Fig. 4: Ceralasertib effect in LCMV infected and tumor-bearing mice.

a Proportion of gp33⁺IFNγ⁺ CD8⁺ T-cells in the spleen of LCMV infected mice treated as indicated on graph n = 10. Individual results, mean and SEM are shown. P values are calculated in one-way ANOVA with correction for multiple comparisons and shown on graphs. NS—p > 0.05. b Percentages of gp33⁺ CD8⁺ T-cells producing IFNγ, TNFα, and IL-2 were evaluated by intracellular staining. Biological replicates (mice) N = 10 are shown. Mean and SEM are shown. P values are calculated in one-way ANOVA with correction for multiple comparisons and shown on graphs. Not significant (p > 0.05). c PD1 expression on gp33⁺ CD8⁺ T-cells. Individual results (mice, N = 8), mean, and SEM are shown. P values were calculated in two-sided unpaired Student’s t-test. d, e Bulk RNAseq analysis of CT26 tumors from mice treated with 25 mg/kg b.i.d. ceralasertib, 10 mg/kg anti-PD-L1 b.i.w. or their combination when on ceralasertib treatment (7 days-on; day 7) and when off-treatment (at the end of 7 days-on/7 days-off cycle; day 14) as indicated. N = 8 for C13, N = 9 for C13 cerala. d Heatmap of Interferon type I signature gene expression, calculated from FPKM normalized counts expressed above biological viable levels, log-transformed and normalized for gene lengths. The data was z-transformed to be visualized in heatmap. e Box plots of median scores and maximum/minimum of interferon type I signature after 7 days on-treatment, or 7 days on/7 days off-treatment (N = 8). The medians were calculated of the log2-transformed FPKM for each sample and significance calculated using Fisher exact T-test. In all panels ns means not significant (p > 0.05). P values are shown on graphs. Source data are provided as a Source Data file.